APX-3330 is a small molecule commercialized by Ocuphire Pharma, with a leading Phase II program in Hepatitis C. According to Globaldata, it is involved in 14 clinical trials, which were completed. GlobalData uses proprietary data and analytics to provide a complete picture of APX-3330’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for APX-3330 is expected to reach an annual total of $66 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
APX-3330 is under development for the treatment of solid tumors including pancreatic ductal adenocarcinoma, pancreatic ductal adenocarcinoma, endometrial cancer, melanoma, chronic hepatitis C, prostate cancer and colorectal cancer, diabetic macular edema, non proliferative diabetic retinopathy (NPDR), proliferative diabetic retinopathy (PDR), hematological cancers including acute lymphoblastic leukemia, malignant peripheral nerve sheath tumor (MPNST), laser-induced choroidal neovascularization, inflammation, inflammatory bowel disease, wet age-related macular degeneration, gall bladder cancer, hepatocellular cancer, bladder cancer and ovarian cancer. It is a new chemical entity and is administered orally as a tablet. The drug candidate acts by targeting Ref-1 and TNF synthesis.
It was also under development for the treatment of hepatic failure and chemotherapy-induced peripheral neuropathy, tuberous sclerosis complex (TSC).
Ocuphire Pharma Overview
Ocuphire Pharma is an ophthalmic biopharmaceutical company that develops and commercializes medicines to treat eye disorders. It is investigating Nyxol, a preservative-free ophthalmic solution for dim light and night vision disturbances (DLD), reversal of Mydriasis (RM), presbyopia, and glaucoma. The company is also evaluates APX3330, an oral pill targeting diabetic retinopathy (DR) and macular edema (DME); and APX2009 drug against wet age-related macular degeneration (WAMD). Ocuphire Pharma seeks to work in partnership with pharmaceutical companies for development and commercialization of its drug candidates. It markets its product under the brand Nyxol. Ocuphire Pharma is headquartered in Farmington Hills, Michigan, the US.
The company reported revenues of (US Dollars) US$39.9 million for the fiscal year ended December 2022 (FY2022), compared to a revenue of US$0.6 million in FY2021. The operating profit of the company was US$18.2 million in FY2022, compared to an operating loss of US$22.7 million in FY2021. The net profit of the company was US$17.9 million in FY2022, compared to a net loss of US$56.7 million in FY2021. The company reported revenues of US$11.9 million for the third quarter ended September 2023, compared to a revenue of US$3.7 million the previous quarter.
For a complete picture of APX-3330’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.